

Supplementary Figures

Fig S1. The age and gender distribution of ACP and PCP group.

Fig S2. The correlation between somatic mutation number and age.

Fig S3. Structure alterations called in each patient.

Fig S4. Kataegis analysis of somatic mutations (SNVs and InDels) in each patient.

Fig S5. The proportion of 96 different extending possible base-pair substitutions of all SNVs identified in ACPs and 10 PCPs.

Fig S6. Schematics for genes listed in Fig. 3a indicating the location of the identified mutations.

Fig S7. IGV graphic report for the alignment of deletion in CTNNB1 CP111 tumor and normal blood sample.

Fig S8. IGV graphic report for the alignment of nonsense mutation of W425X in FBXW7 of CP22 tumor and normal blood sample.

Fig S9. CTNNB1 mRNA stability in CTNNB1-WT/Mut 293T/HCT116 cells.




Fig S1. The age and gender distribution of ACP and PCP group.






Fig S2. The correlation between somatic mutation number and age.


CP24




CP25




CP26




CP27




CP28




CP31




CP32




CP33




CP34




CP111



CP133



CP176








Fig S3. Structure alterations called in each patient.


■ C>A
 ■ C>G
 ■ C>T
 ■ T>A
 ■ T>C
 ■ T>G
 ■ Other




Total somatic mutation - CP11




Total somatic mutation - CP12




Total somatic mutation – CP13




Total somatic mutation – CP15




Total somatic mutation - CP16




Total somatic mutation - CP18




Total somatic mutation – CP19




Total somatic mutation – CP20




Total somatic mutation - CP21




Total somatic mutation - CP22




Total somatic mutation - CP23




Total somatic mutation - CP24




Total somatic mutation – CP25




Total somatic mutation – CP26




Total somatic mutation – CP27




Total somatic mutation – CP28




Total somatic mutation - CP31




Total somatic mutation - CP32




Total somatic mutation – CP33




Total somatic mutation – CP34




Total somatic mutation – CP111




Total somatic mutation – CP133



Total somatic mutation – CP176



Total somatic mutation – CP177






Fig S4. Kataegis analysis of somatic mutations (SNVs and InDels) in each patient.




Fig S5. The proportion of 96 different extending possible base-pair substitutions of all SNVs identified in 16 ACPs and 10 PCPs.




Fig S6. Schematics for genes listed in Fig. 3a indicating the location of the identified mutations.




Fig S7. IGV graphic report for the alignment of deletion in CTNNB1 CP111 tumor and normal blood sample.




Fig S8. IGV graphic report for the alignment of nonsense mutation of W425X in FBXW7 of CP22 tumor and normal blood sample.




Fig S9. CTNNB1 mRNA stability in CTNNB1-WT/Mut 293T/HCT116 cells. a-b CTNNB1 mRNA stability in CTNNB1-WT/Mut 293T/HCT116 treated with 5 $\mu\text{g}/\text{mL}$ actinomycin D at different time points. Actin mRNA was used as a negative control.